Skip to main content
Premium Trial:

Request an Annual Quote

Packard Files for Follow-on Offering

NEW YORK, Feb 9 - Packard BioScience said Friday it had filed a statement with the US Securities and Exchange Commission for a follow-on offering of 10 million shares.

Packard of Meriden, Conn., said it would issue three million of the shares, while shareholders, including CEO Emery Olcott and Senior Vice President Richard McKernan, intend to sell an additional seven million shares.

Packard will only receive proceeds from the shares which its sells. The company estimated that it would raise a net $41.25 million from the sale of the shares, which it plans to use for “general corporate purposes.”

The company also expects to generate net proceeds of $120 million to $130 million from the sale of its Canberra division. The sale is expected to close in during the first quarter of this year.

The company had actual cash and cash equivalents of $52.8 million, at the end of September 2000, the last date for which such a figure was available.

Packard’s shares were down 2 3/8, or 16 percent, at 12 1/4 in morning trading.

Me rrill Lynch, Credit Suisse First Boston, J.P. Morgan, Banc of America Securities, and Robert W. Baird are underwriting the offering.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.